ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Bristol Myers Squibb to acquire Forbius
August 26, 2020Forbius’s lead TGF-beta asset, AVID200, is an isoform-selective TGF-beta inhibitor, currently in Phase 1 for oncology and fibrosis. -
Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200
January 10, 2019Forbius announced the first patient was dosed in a Phase 1 clinical trial with AVID200. The trial will evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor effects of escalating doses of AVID200 in patients with solid tumors..... -
CPRIT Awards Forbius Product Development Grant
August 28, 2018Forbius (Formation Biologics) has been awarded a Product Development grant totaling $18.75 million from the Cancer Prevention and Research Institute of Texas (CPRIT).
Pharma Sources Insight January 2025
